Search results
Results From The WOW.Com Content Network
BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced its 2025 outlook and key catalysts for ...
On Tuesday, Annexon Inc (NASDAQ:ANNX) released topline results from its Phase 3 trial in patients with Guillain-Barré syndrome (GBS), an autoimmune condition in which the immune system attacks ...
BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of William “BJ” Jones to its board of directors.
The drug, ANX005, was tested in 241 patients with GBS and met the main goal of the study. Annexon has begun another trial to confirm the results in U.S. patients. (Reuters) -Annexon said on ...
The average of price targets set by Wall Street analysts indicates a potential upside of 241.4% in Annexon, Inc. (ANNX). While the effectiveness of this highly sought-after metric is questionable ...
He is a co-founder of Annexon Biosciences, Inc., a company making drugs to block neurodegeneration in Alzheimer's and other neurological diseases. [39] He became a member and elected Fellow of the American Association for the Advancement of Science in 2011. [40]
Arnon Rosenthal (Hebrew: ארנון רוזנטל) is an Israeli-American neuroscientist, inventor, and biotechnology entrepreneur.. Rosenthal is an inventor and developer of the pain medicine tanezumab, the migraine medicine fremanezumab, the Alzehimer's drug ponezumab and the target for the basal cell carcinoma medicine vismodegib.
Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration ...